The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis

References

• Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther. 2021;11(3):1053–1064. doi:10.1007/s13555-021-00518-8
   Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;m1590. doi:10.1136/bmj.m1590
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. IJMS. 2019;20(6):1475. doi:10.3390/ijms20061475
   Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790. doi:10.1111/jdv.14114
   PubMed Web of Science ®Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. IJMS. 2017;18(11):2297. doi:10.3390/ijms18112297
   Web of Science ®Google Scholar
• Nast A, Altenburg A, Augustin M, et al. German S3‐guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: treatment goals and treatment recommendations. JDDG. 2021;19(6):934.
   Google Scholar
• Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425–442. doi:10.1007/s40257-021-00603-w
   PubMed Web of Science ®Google Scholar
• de Ruiter CC, Rustemeyer T. Biologics can significantly improve Dermatology Life Quality Index (DLQI) in psoriatic patients: a systematic review. PTT. 2022;12:99–112. doi:10.2147/PTT.S356568
   Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519. doi:10.1111/bjd.16102
   PubMed Web of Science ®Google Scholar
• Tobin P, Richards D, Callender R, Wilson C. Protein engineering: a new frontier for biological therapeutics. CDM. 2015;15(7):743–756. doi:10.2174/1389200216666141208151524
   Google Scholar
• Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Didriksen Apol E, Jemec GB. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatolog Treat. 2020;33(1):204–218. doi:10.1080/09546634.2020.1743811
   PubMed Web of Science ®Google Scholar
• ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF/IL‐23/IL‐17 axis—head‐to‐head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92. doi:10.1111/sji.12946
   Web of Science ®Google Scholar
• Furue K, Ito T, Furue M. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine. 2018;111:182–188. doi:10.1016/j.cyto.2018.08.025
   PubMed Web of Science ®Google Scholar
• Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158(5):513. doi:10.1001/jamadermatol.2022.0364
   PubMed Web of Science ®Google Scholar
• Ratner M. IL-17–targeting biologics AIM to become standard of care in psoriasis. Nat Biotechnol. 2015;33(1):3–4. doi:10.1038/nbt0115-3
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579. doi:10.1007/s40257-021-00598-4
   PubMed Web of Science ®Google Scholar
• Egeberg A, Danø A, Pedersen MH, Sohrt A, Borg E, Notario J. Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain. J Med Econ. 2021;24(1):1134–1142. doi:10.1080/13696998.2021.1970953
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)‑17 and IL‑23 inhibitors for the treatment of psoriasis: a retrospective multi‑country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904. doi:10.1007/s40257-022-00722-y
   PubMed Web of Science ®Google Scholar
• Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermo Sifiliogr. 2016;107(7):577–590. doi:10.1016/j.ad.2016.04.018
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela Snr E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. PTT. 2022;12:127–137. doi:10.2147/PTT.S367744
   Google Scholar
• Armstrong AW, Soliman AM, Betts KA, et al. Long-term benefit–risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther. 2022;12(1):167–184. doi:10.1007/s13555-021-00647-0
   PubMed Web of Science ®Google Scholar
• Nyholm N, Schnack H, Danø A, Skowron F. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany. Curr Med Res Opin. 2023;39(6):833–842. doi: 10.1080/03007995.2023.2214046
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bimzelx®: summary of product characteristics; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf. Accessed July 12, 2023.
   Google Scholar
• European Medicines Agency. Cosentyx®: summary of product characteristics; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf. Accessed July 12, 2023.
   Google Scholar
• European Medicines Agency. Kyntheum®: summary of product characteristics; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf. Accessed July 12, 2023.
   Google Scholar
• European Medicines Agency. Taltz: summary of product characteristics; 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf. Accessed July 12, 2023.
   Google Scholar
• Egeberg A, Freilich J, Stelmaszuk MN, et al. Real-world dose adjustments of biologic treatments in psoriasis and their economic impact - a Swedish national population study. Clin Exp Dermatol. 2022;47:1968–1975. doi:10.1111/ced.15288
   PubMed Web of Science ®Google Scholar
• Gambardella A, Licata G, Sohrt A. Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review. Dermatol Ther. 2021;11(4):1141–1156. doi:10.1007/s13555-021-00559-z
   Web of Science ®Google Scholar
• Codifa. Codifa - L’Informatore Farmaceutico [Codifa - Pharmaceutical Informer]; 2022. Available from: https://www.codifa.it/. Accessed July 12, 2023.
   Google Scholar
• ABDATA Pharma-Daten-Service. Pharmaceutical manufacturer prices in Germany; 2023.
   Google Scholar
• Augustin M, Wirth D, Mahlich J, Pepper AN, Druchok C. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. J Dermatolog Treat. 2020;33(2):976–982. doi:10.1080/09546634.2020.1793891
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco. Modifica dell’allegato n. 2 della determina n. 285/2022 del 27 giugno 2022, concernente procedura pay-back 5% [Amendment of attachment no. 2 of decision n. 285/2022 of 27 June 2022, concerning the 5% pay-back procedure]; 2022. Available from: https://www.aifa.gov.it/. Accessed July 12, 2023.
   Google Scholar
• Di Matteo S, Cavaliere A, Danesi R. Terapie biologiche e sequenze di trattamento per i pazienti con psoriasi a placche moderata-grave: un’analisi farmacoeconomica per il Sistema Sanitario Nazionale italiano. Clinico Economics; 2022. Available from: http://www.clinicoeconomics.eu/articles/flipbook/17_2022_137-154/. Accessed July 12, 2023.
   Google Scholar